Thyroid Eye Disease

KOLOA, Hawaii — Effective management of thyroid eye disease requires a focus on mitigating modifiable risk factors, according to a presenter at Hawaiian Eye 2025.

NEW YORK — In this presentation from OSN New York Retina, Nicholas Mahoney, MD, discusses thyroid eye disease.

A decrease in the number of orbital decompression surgeries in patients with thyroid eye disease may be attributed to the introduction of teprotumumab treatment, according to a study published in Canadian Journal of Ophthalmology.

Prevent Blindness has declared Sept. 16 to 22 as Inflammatory Eye Disease Awareness Week and is offering free educational resources and expert videos for the public and eye care providers.

Viridian Therapeutics reported positive topline data from the phase 3 THRIVE clinical trial of veligrotug for the treatment of active thyroid eye disease.

CARLSBAD, Calif. — In this Healio Video Perspective from the Women in Ophthalmology Summer Symposium, Lisa M. Nijm, MD, JD, discusses the burden of thyroid eye disease and how it affects quality of life.

CARLSBAD, Calif. — In this Healio Video Perspective from the Women in Ophthalmology Summer Symposium, Amina I. Malik, MD, of Houston Methodist in Texas explains why comanagement must be embraced to treat certain ocular conditions.

Less than 25% of patients with thyroid eye disease who underwent a full course of treatment with Tepezza required re-treatment, according to a study published in Ophthalmology.